- Home
- KLRS vs HYPR Comparison
KLRS vs HYPR Comparison
Compare KLRS & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- HYPR
- Stock Information
- Founded
- KLRS 2019
- HYPR 2014
- Country
- KLRS United States
- HYPR United States
- Employees
- KLRS N/A
- HYPR N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- HYPR Medical Specialities
- Sector
- KLRS Health Care
- HYPR Health Care
- Exchange
- KLRS Nasdaq
- HYPR Nasdaq
- Market Cap
- KLRS 129.0M
- HYPR 54.6M
- IPO Year
- KLRS N/A
- HYPR N/A
- Fundamental
- Price
- KLRS $3.89
- HYPR $0.72
- Analyst Decision
- KLRS Buy
- HYPR Strong Buy
- Analyst Count
- KLRS 1
- HYPR 3
- Target Price
- KLRS N/A
- HYPR $1.33
- AVG Volume (30 Days)
- KLRS 62.9K
- HYPR 183.4K
- Earning Date
- KLRS 05-19-2025
- HYPR 05-13-2025
- Dividend Yield
- KLRS N/A
- HYPR N/A
- EPS Growth
- KLRS N/A
- HYPR N/A
- EPS
- KLRS N/A
- HYPR N/A
- Revenue
- KLRS N/A
- HYPR $12,890,000.00
- Revenue This Year
- KLRS N/A
- HYPR $24.00
- Revenue Next Year
- KLRS N/A
- HYPR $28.70
- P/E Ratio
- KLRS N/A
- HYPR N/A
- Revenue Growth
- KLRS N/A
- HYPR 16.84
- 52 Week Low
- KLRS $4.19
- HYPR $0.58
- 52 Week High
- KLRS $24.15
- HYPR $1.90
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- HYPR 45.92
- Support Level
- KLRS N/A
- HYPR $0.66
- Resistance Level
- KLRS N/A
- HYPR $0.76
- Average True Range (ATR)
- KLRS 0.00
- HYPR 0.05
- MACD
- KLRS 0.00
- HYPR 0.01
- Stochastic Oscillator
- KLRS 0.00
- HYPR 39.08
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.